ASCO Survey on COVID-19 in Oncology (ASCO) Registry
ASCO Survey on Coronavirus Disease 2019 (COVID-19) in Oncology (ASCO) Registry
1 other identifier
observational
7,000
1 country
77
Brief Summary
The American Society of Clinical Oncology (ASCO) Survey on Coronavirus 2019 (COVID-19) in Oncology Registry (ASCO Registry) aims to help the cancer community learn more about the patterns of symptoms and severity of COVID-19 among patients with cancer, as well as how COVID-19 is impacting the delivery of cancer care and patient outcomes. The ASCO Registry collects both baseline and follow-up data on how the virus impacts cancer care and cancer patient outcomes during the COVID-19 pandemic.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2020
Longer than P75 for all trials
77 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 19, 2020
CompletedFirst Submitted
Initial submission to the registry
November 30, 2020
CompletedFirst Posted
Study publicly available on registry
December 9, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2025
CompletedJuly 24, 2023
July 1, 2023
4.3 years
November 30, 2020
July 20, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Changes to Cancer Treatments
Treatments: Yes vs. no response to changes in reported treatment administration for anti-cancer therapeutics
24 months
Secondary Outcomes (7)
All-cause mortality at 30 days
30 days
COVID-19 Symptoms
24 months
COVID-19 Treatments
24 months
Patient vital status
24 months
Overall survival
24 months
- +2 more secondary outcomes
Eligibility Criteria
Patients with a cancer diagnosis who have a confirmed SARS-CoV-2 infection and are being treated for their cancer at participating cancer practices/institutions within the United States
You may qualify if:
- COVID-19 positive diagnosis
- One of the following;
- Patient has active cancer at the time of COVID-19 diagnosis OR
- Patient has been cancer-free for less than 12 months AND receiving adjuvant therapy at the time of COVID-19 diagnosis
You may not qualify if:
- COVID-19 suspected, but no positive test result
- Patient is a cancer-free not receiving any anti-cancer or adjuvant treatment
- Patient is receiving adjuvant therapy, but has been cancer-free for up to 12 months at the time of COVID-19 diagnosis
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (77)
University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
Infirmary Cancer Care
Mobile, Alabama, 36607, United States
Anchorage Oncology Center
Anchorage, Alaska, 99508, United States
AIS Cancer Center
Bakersfield, California, 93301, United States
Long Beach Memorial Medical Center
Fountain Valley, California, 92708, United States
Orange Coast Medical Center
Fountain Valley, California, 92708, United States
Saddleback Memorial Medical Center
Fountain Valley, California, 92708, United States
Helen Diller Family Comprehensive Cancer Center, UCSF
San Francisco, California, 94118, United States
Gene Upshaw Memorial Tahoe Forest Cancer Center
Truckee, California, 96161, United States
PIH Health
Whittier, California, 90602, United States
Hartford HealthCare Cancer Institute
Hartford, Connecticut, 06102, United States
Day Kimball Healthcare
Putnam, Connecticut, 06260, United States
Bayhealth Medical Center
Dover, Delaware, 19901, United States
Florida Precision Oncology, A Division of 21st Centry Oncology
Fort Myers, Florida, 33907, United States
Florida Cancer Specialists - Sarah Cannon Research Institute
Sarasota, Florida, 34236, United States
University of South Florida
Tampa, Florida, 33612, United States
Emory University Winship Cancer Institute
Atlanta, Georgia, 30322, United States
Augusta University
Augusta, Georgia, 30912, United States
Cancer Center of Middle Georgia, LLC
Dublin, Georgia, 31021, United States
Hawaii Cancer Care
Honolulu, Hawaii, 96813, United States
University of Chicago
Chicago, Illinois, 60637, United States
NorthShore University HealthSystem
Evanston, Illinois, 60201, United States
OSF Little Company of Mary Hospital
Evergreen Park, Illinois, 60805, United States
Joliet Oncology-Hematology Associates
Joliet, Illinois, 60435, United States
Edward-Elmhurst Healthcare
Naperville, Illinois, 60540, United States
Illinois Cancer Care
Peoria, Illinois, 61615, United States
Quincy Medical Group Cancer Institute
Quincy, Illinois, 62301, United States
Goshen Center for Cancer Care
Goshen, Indiana, 46526, United States
Michiana Hematology Oncology
Mishawaka, Indiana, 46545, United States
Midwest Oncology Associates - Sarah Cannon Research Institute
Overland Park, Kansas, 66215, United States
University of Kansas Medical Center
Westwood, Kansas, 66205, United States
Baptist Health Madisonville
Madisonville, Kentucky, 42431, United States
Greater Baltimore Medical Center
Baltimore, Maryland, 21204, United States
Saint Agnes Hospital Cancer Institute
Baltimore, Maryland, 21229, United States
Tufts Medical Center
Boston, Massachusetts, 02111, United States
Great Lakes Cancer Management Specialists
Grosse Pointe Woods, Michigan, 48236, United States
Mayo Clinic
Rochester, Minnesota, 55905, United States
Boone Hospital Center
Columbia, Missouri, 65201, United States
Mosaic Cancer Care
Saint Joseph, Missouri, 64507, United States
Nebraska Hematology Oncology
Lincoln, Nebraska, 68506, United States
Callahan Cancer Center
North Platte, Nebraska, 69101, United States
Nebraska Cancer Specialists
Omaha, Nebraska, 68130, United States
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
Bayonne Medical Center
Bayonne, New Jersey, 07002, United States
CarePoint Health - Christ Hospital
Jersey City, New Jersey, 07306, United States
Penn Medicine, Princeton Health
Plainsboro, New Jersey, 08536, United States
Hematology Oncology Associates of Central New York
East Syracuse, New York, 13057, United States
Northwell Health Cancer Institute
Lake Success, New York, 11042, United States
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States
Levine Cancer Institute Atrium Health
Charlotte, North Carolina, 28204, United States
East Carolina University
Greenville, North Carolina, 27858, United States
Carteret Health Care
Morehead City, North Carolina, 28557, United States
CarolinaEast Medical Center
New Bern, North Carolina, 28560, United States
Regional Medical Oncology Center
Wilson, North Carolina, 27893, United States
Aultman Hospital
Canton, Ohio, 44710, United States
Cincinnati Children's Hospital
Cincinnati, Ohio, 45229, United States
Oncology Hematology Care
Cincinnati, Ohio, 45242, United States
University Hospitals Seidman Cancer Center
Cleveland, Ohio, 44106, United States
TriCounty Hematology and Oncology
Massillon, Ohio, 44646, United States
Columbia Memorial Hospital
Astoria, Oregon, 97103, United States
Samaritan Health Services Corvallis
Corvallis, Oregon, 97330, United States
Penn Medicine, Lancaster General Health
Lancaster, Pennsylvania, 17604, United States
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
Lexington Oncology
West Columbia, South Carolina, 29169, United States
Monument Health
Rapid City, South Dakota, 57701, United States
Kirkland Cancer Center
Jackson, Tennessee, 38301, United States
Baptist Clinical Research Institute
Memphis, Tennessee, 38120, United States
Tennessee Oncology
Nashville, Tennessee, 37203, United States
The START Center for Cancer Care
San Antonio, Texas, 78229, United States
University of Texas, Health Science Center
San Antonio, Texas, 78229, United States
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States
Augusta Health
Fishersville, Virginia, 22939, United States
Hematology Oncology Associates of Fredericksburg
Fredericksburg, Virginia, 22408, United States
Virginia Cancer Institute
Richmond, Virginia, 23230, United States
PeaceHealth
Vancouver, Washington, 98664, United States
Related Publications (5)
Mullangi S, Aviki EM, Hershman DL. Reexamining Social Determinants of Health Data Collection in the COVID-19 Era. JAMA Oncol. 2022 Dec 1;8(12):1736-1738. doi: 10.1001/jamaoncol.2022.4543.
PMID: 36301554BACKGROUNDKurbegov D, Bruinooge SS, Lei XJ, Kirkwood MK, Dickson N, Hattiangadi T, Mileham KF, Patrick A, Williams JH, Kaltenbaugh M, Gralow JR, Garrett-Mayer E. Rate of COVID-19 vaccination among patients with cancer who tested positive for severe acute respiratory syndrome-coronavirus 2: Analysis of the American Society of Clinical Oncology Registry. Cancer. 2023 Jun 1;129(11):1752-1762. doi: 10.1002/cncr.34726. Epub 2023 Mar 15.
PMID: 36920457RESULTMileham KF, Bruinooge SS, Aggarwal C, Patrick AL, Davis C, Mesenhowski DJ, Spira A, Clayton EJ, Waterhouse D, Moore S, Jazieh AR, Chen RC, Kaltenbaugh M, Williams JH, Gralow JR, Schilsky RL, Garrett-Mayer E. Changes Over Time in COVID-19 Severity and Mortality in Patients Undergoing Cancer Treatment in the United States: Initial Report From the ASCO Registry. JCO Oncol Pract. 2022 Apr;18(4):e426-e441. doi: 10.1200/OP.21.00394. Epub 2021 Oct 25.
PMID: 34694907RESULTLlanos AAM, Ashrafi A, Ghosh N, Tsui J, Lin Y, Fong AJ, Ganesan S, Heckman CJ. Evaluation of Inequities in Cancer Treatment Delay or Discontinuation Following SARS-CoV-2 Infection. JAMA Netw Open. 2023 Jan 3;6(1):e2251165. doi: 10.1001/jamanetworkopen.2022.51165.
PMID: 36637818RESULTMullangi S, Aviki EM, Chen Y, Robson M, Hershman DL. Factors Associated With Cancer Treatment Delay Among Patients Diagnosed With COVID-19. JAMA Netw Open. 2022 Jul 1;5(7):e2224296. doi: 10.1001/jamanetworkopen.2022.24296.
PMID: 35900758RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Julie R Gralow, MD
American Society of Clinical Oncology
- STUDY DIRECTOR
Suanna S Bruinooge, MPH
American Society of Clinical Oncology
- STUDY DIRECTOR
Elizabeth Garrett-Mayer, PhD
American Society of Clinical Oncology
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Target Duration
- 24 Months
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 30, 2020
First Posted
December 9, 2020
Study Start
April 19, 2020
Primary Completion
August 1, 2024
Study Completion
January 1, 2025
Last Updated
July 24, 2023
Record last verified: 2023-07
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP
- Time Frame
- First Quarter 2022
- Access Criteria
- Completion of a satisfactory Research Project Proposal Application, as discussed on the ASCO Data Library website
ASCO is making deidentified Registry data available to researchers (both those at Registry sites and those not involved with the Registry) who submit a qualified research proposal for further analysis. ASCO reviews requests for Registry data from individuals and entities that submit a research proposal that complies with ASCO's requirements for data access. ASCO will promote access to information for projects that address the needs of patients with cancer, including marginalized populations and communities. ASCO will promote authenticity, quality, reliability and integrity of information and analyses. ASCO will promote fair access and efficiency in the use and sharing of ASCO Information within the bounds of this Policy.